Q3 2024 Earnings Call Transcript November 5, 2024 Apellis Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.46 EPS, expectations were $-0.32. Operator: Good morning, ladies ...

Apellis Pharmaceuticals Inc (APLS) reports significant revenue growth but faces market and regulatory hurdles in Q3 2024.

Apellis Pharmaceuticals (APLS) stock falls as company's Q3 2024 financials disappoint with lower-than-expected U.S. sales ...

Generated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product salesGrew SYFOVRE® (pegcetacoplan injection) demand by 7% quarter-over-quarter, with U.S. net product revenue ...

Four months after Europe's Committee for Medicinal Products for Human Use (CHMP) rejected Apellis’ GA application for Syfovre for a second time, Astellas has withdrawn its application for the approval ...

A drug against fungal infections in cancer patients can last twice as long in people with obesity, and may make chemotherapy ...

On Monday, Citi reaffirmed its Buy rating on Apellis Pharmaceuticals (NASDAQ:APLS) stock with a steady price target of $63.00. The endorsement follows the company's presentation at the American ...

Astellas confirmed today that it will withdraw its EMA filing for avacincaptad pegol as a treatment for eye disorder ...

On Monday, Citi reaffirmed its Buy rating on Apellis Pharmaceuticals (NASDAQ:APLS) stock with a steady price target of $63.00. The endorsement follows the company's presentation at the American ...

Apellis (APLS) Pharmaceuticals and Sobi announced that results from the Phase 3 VALIANT study were presented as an oral presentation during the High-Impact Clinical Trials session at the American ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...